The use of phytotherapy expands the possibility of therapeutic resources for the population, often offering reduced costs when compared to the pharmaceutical industry. In this perspective, the JACBIO® dermocosmetic ointment revealed, in non-clinical trials, its antibacterial and healing potential, with a great stimulating effect in increasing the production of images. This work aimed to carry out the clinical phase study on dermal toxicity, in serious humans, by applying JACBIO®, based on extracts from the leaves of Piptadenia gonoacantha (Pau Jacaré). The phase I randomized clinical trial was carried out with 28 clinically healthy patients at a public university in Minas Gerais, with no period from August to December 2018. The toxicological trial was developed with the intervention group that received a JACBIO® dermatological ointment and the Placebo group. From the experimental protocol, participants were followed for four weeks. An analysis between the ointment and placebo groups, without reference to anticholinergic and cardiovascular events, showed no statistically significant difference. Likewise, there was no difference in laboratory results performed before and after treatment, both for the placebo group and for the intervention group. A low toxicity of the product indicates that this adjustment is safe and serves as a basis for phase II clinical trials in patients with lesions.

The search for herbal innovations with medicinal properties has intensified. As for this matter, the extracts of Piptadenia gonoacantha, present antimicrobial, anti-inflammatory and antinociceptive action, as well as absence of proven toxicity. The objective was to evaluate the antibacterial action of formulations containing extracts of Piptadenia gonoacantha. The extract was prepared and characterized by liquid chromatography coupled to mass spectrometry (UPLC-MS/MS). This was used for the development of cream, ointment, gel, balm and liquid soaps formulations, being submitted to evaluation, along with the extracts, for antibacterial activity. The characterization of the extract revealed the presence of rutin, ferulic acid, p-coumaric acid, quercitrin, canferol, apigenin and 6-hydroxycoumarin in their constitution. The formulations presented inhibition halos against strains of S. aureus and S. epidermides, with mean efficiency, relative to the positive control, of 47% to 99%. The best results were found for the S. epidermides strain with a mean of 91.5% efficiency in relation to the control. The presence of the metabolites observed in the characterization of the extract justifies the antibacterial action observed in its evaluation, as well as to the formulations. The formulations evaluated have promising antibacterial activity as natural therapeutic alternatives for the treatment of infectious processes.